Angiotech Pharmaceuticals, Inc. - New study shows that Zilver(R) PTX(TM) effectively treats blockages in critical thigh artery



    VANCOUVER, April 14 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:  
ANPI, TSX: ANP) today announced its corporate partner, Cook Medical, reported
data on two-year follow up that showed that 82 percent of patients who were
treated with Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent
(DES) were free from reintervention at two-year follow up. The Zilver PTX
Registry study, involving 792 patients from across the world, is assessing the
safety and efficacy of the Zilver PTX in treating PAD. The most recent results
were reported at the 31st International Symposium: Charing Cross Controversies
Challenges Consensus.
    "These results are extremely encouraging as it's the first time
paclitaxel-coated stents have been used in the treatment of blockages in
arteries outside the heart," said Zilver PTX global principal investigator,
Dr. Michael Dake, Professor in the Department of Cardiothoracic Surgery at
Stanford University Medical School and Medical Director of the Cath/Angio
Laboratories at Stanford University Medical Center. "Patients treated with the
Zilver PTX had a very low complication rate and required fewer
reinterventions."
    Data was compiled at 12 and 24 months for 593 patients and 177 patients
respectively from the registry study, which enrolled a broad spectrum of
patients, including those with complex lesions (e.g., long lesions, total
occlusions, in-stent restenosis). The corresponding event-free survival (EFS)
rates were 87 percent and 78 percent, and freedom from TLR (target lesion
revascularization) was 89 percent and 82 percent. Clinical measures that
included ankle-brachial index, Rutherford score, and walking distance and
speed scores showed significant improvement at six and 12 months and were
maintained through 24 months.
    Detailed evaluation of stent x-rays demonstrated excellent stent
integrity through 12 months, confirming previously published results showing
99 percent completely intact stents with a mean follow up of 2.4 years in the
challenging superior femoral artery and popliteal arteries, including behind
the knee locations.
    One in five in the 65- to 75-year-old age group in the UK(*) has peripheral
arterial disease (PAD). Yet only a quarter of these people have any symptoms
at all. The 'silent' nature of this condition can result in a number of
patients being diagnosed only when their condition has progressed to the
severe stage. In patients with severe PAD whose condition is not improving
with risk-factor modification, exercise programs and pharmacological therapy,
invasive procedures may need to be carried out. These procedures include
angioplasty, stenting or surgery.
    "We are impressed with both the efficacy and durability demonstrated by
the Zilver PTX in the registry study and believe we will see similar results
in the US randomized trial which is currently ongoing," said Dr. Bill Hunter,
President and CEO of Angiotech. "Our partner, Cook Medical, has been committed
to continually improving the efficacy and safety of peripheral DES and early
results suggest that the self-expanding, Zilver PTX stent will be an important
treatment option for patients with PAD."
    In addition to the registry arm of the study, the 480 patient randomized
component is designed to evaluate the Zilver PTX across 45 trial sites in the
United States, Japan and Europe. Of the 480 patients enrolled in the
randomized study, 240 received the Zilver PTX DES. Enrollment in the
randomized study was completed in 2008. For more information, please visit
www.zilverptxtrial.com.

    
    (*) Fowkes FGR, Housley E, Cawood EHH, MacIntyre CAA, Ruckley CV,
    Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and
    symptomatic peripheral arterial disease in the general population. Int J
    Epidemiol 1991;20:384-91.
    

    Cook licenses the rights to use paclitaxel with peripheral stents and
other non-coronary medical devices from Angiotech. Under the terms of its 1997
license agreement with Cook, Angiotech is entitled to ereceive royalty
payments upon the commercial sale of paclitaxel-eluting peripheral vascular
products, including the Zilver PTX.

    
    Forward Looking Statements
    --------------------------
    
    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2009 and beyond, our strategies
or future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research, development, product
and drug development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are taken into
account as part of our assumptions underlying these forward-looking statements
and include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing products or our
ability to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products sold by our partners;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement for
substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and
any other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from third
party challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission ("SEC") and
applicable Canadian regulatory authorities. For a more thorough discussion of
the risks associated with our business, see the "Risk Factors" section in our
annual report for the year ended December 31, 2008 filed with the SEC on Form
10-K.

    Given these uncertainties, assumptions and risk factors, readers are 
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.

    (C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at www.angiotech.com.





For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,
dede.sheel@fdashtonpartners.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890